Sign In
to Vote &
Create Storyboards.
 
SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat central nervous system (CNS) diseases, has announced new data presented at the American Epilepsy Society (AES) Annual Meeting that reveal a novel mechanism and approach for the treatment of status epilepticus (SE) and identify new, orally bioavailable compounds that may lead to improved therapies for chronic epilepsies."Epilepsy is among many disorders of the CNS that have a critical unmet need," said Al Robichaud...
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard